THERAPY DOSSIER · th-0b0cecae1269

Pituitary adenylate cyclase-activating polypeptide (PACAP)

Hormone

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03814226 ↗NAunknown

Effect of PACAP-38 infusion in inducing headache in patients with cluster headache

Cluster Headache

Enrolment: 45 · Results not recorded

NCT04960657 ↗NAcompleted

Haemodynamic effects of PACAP38 after glibenclamide administration in healthy volunteers

Migraine · Headache · Pain

Enrolment: 22 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30443839 ↗2018Reported benefit

Protective Effect of PACAP on Ischemia/Reperfusion-Induced Kidney Injury of Male and Female Rats: Gender Differences.

RatIschaemia-reperfusionRenalWistarMale and femaleIntravenousBefore arterial clamping

Model: Unilateral renal artery clamping followed by 24 h, 48 h or 14 day reperfusion

Tubular damage was significantly less severe in PACAP-treated male and female rats than in controls, with cytokine, oxidative stress and antioxidant findings consistent with the histology; females showed less pronounced injury than males in both treated and untreated groups.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…